Mercury Laboratories
Market Cap
₹526.1m
Last Updated
2020/10/28 12:42 UTC
Data Sources
Company Financials
Executive Summary
Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare in Asia, Africa, the Far East, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet and fair value.
Share Price & News
How has Mercury Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 538964's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-11.8%
538964
-1.0%
IN Pharmaceuticals
-0.2%
IN Market
1 Year Return
53.8%
538964
44.2%
IN Pharmaceuticals
0.2%
IN Market
Return vs Industry: 538964 exceeded the Indian Pharmaceuticals industry which returned 44.2% over the past year.
Return vs Market: 538964 exceeded the Indian Market which returned 0.2% over the past year.
Shareholder returns
| 538964 | Industry | Market | |
|---|---|---|---|
| 7 Day | -11.8% | -1.0% | -0.2% |
| 30 Day | -1.5% | 0.09% | 4.8% |
| 90 Day | 38.1% | 10.2% | 6.9% |
| 1 Year | 54.6%53.8% | 46.1%44.2% | 2.0%0.2% |
| 3 Year | -0.4%-1.8% | 23.4%20.0% | -2.4%-7.2% |
| 5 Year | -6.2%-8.2% | 0.2%-3.4% | 39.9%29.3% |
Price Volatility Vs. Market
How volatile is Mercury Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Mercury Laboratories undervalued compared to its fair value and its price relative to the market?
15.56x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 538964 (₹413.75) is trading above our estimate of fair value (₹264.81)
Significantly Below Fair Value: 538964 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 538964 is good value based on its PE Ratio (15.6x) compared to the IN Pharmaceuticals industry average (22.6x).
PE vs Market: 538964 is good value based on its PE Ratio (15.6x) compared to the Indian market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 538964's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 538964 is good value based on its PB Ratio (1.6x) compared to the IN Pharmaceuticals industry average (2.2x).
Next Steps
Future Growth
How is Mercury Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
27.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mercury Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether Mercury Laboratories is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Mercury Laboratories competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Mercury Laboratories performed over the past 5 years?
-1.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 538964 has high quality earnings.
Growing Profit Margin: 538964's current net profit margins (5.7%) are higher than last year (5.3%).
Past Earnings Growth Analysis
Earnings Trend: 538964's earnings have declined by 1.6% per year over the past 5 years.
Accelerating Growth: 538964's earnings growth over the past year (5.5%) exceeds its 5-year average (-1.6% per year).
Earnings vs Industry: 538964 earnings growth over the past year (5.5%) underperformed the Pharmaceuticals industry 14.7%.
Return on Equity
High ROE: 538964's Return on Equity (10%) is considered low.
Next Steps
Financial Health
How is Mercury Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 538964's short term assets (₹315.1M) exceed its short term liabilities (₹150.7M).
Long Term Liabilities: 538964's short term assets (₹315.1M) exceed its long term liabilities (₹92.6M).
Debt to Equity History and Analysis
Debt Level: 538964's debt to equity ratio (19.8%) is considered satisfactory.
Reducing Debt: 538964's debt to equity ratio has reduced from 44.5% to 19.8% over the past 5 years.
Debt Coverage: 538964's debt is well covered by operating cash flow (86.8%).
Interest Coverage: 538964's interest payments on its debt are well covered by EBIT (6x coverage).
Balance Sheet
Next Steps
Dividend
What is Mercury Laboratories's current dividend yield, its reliability and sustainability?
0.48%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 538964's dividend (0.48%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.55%).
High Dividend: 538964's dividend (0.48%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 538964 has been paying a dividend for less than 10 years.
Growing Dividend: 538964's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (7.5%), 538964's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average board tenure
CEO
Rajendra Shah (68 yo)
no data
Tenure
₹1,840,793
Compensation
Mr. Rajendra Ramanlal Shah has been the Managing Director of Mercury Laboratories Limited since March 31, 1992 and serves as its Chief Executive Officer and served as its Chairman of the Board until Februa ...
CEO Compensation Analysis
Compensation vs Market: Rajendra's total compensation ($USD24.99K) is below average for companies of similar size in the Indian market ($USD54.82K).
Compensation vs Earnings: Rajendra's compensation has been consistent with company performance over the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | no data | ₹1.84m | 24.56% ₹ 129.2m | |
| Non-Executive Non Independent Director | 38.67yrs | ₹10.00k | 34.24% ₹ 180.2m | |
| Non Executive Independent Director | 5.42yrs | ₹20.50k | no data | |
| Non Executive Independent Chairman | 0.67yr | ₹42.00k | no data | |
| Non Executive Non Independent Director | 3yrs | ₹961.00k | no data | |
| Additional Director | 0.67yr | no data | 8.67% ₹ 45.6m |
4.2yrs
Average Tenure
66.5yo
Average Age
Experienced Board: 538964's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Mercury Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mercury Laboratories Limited
- Ticker: 538964
- Exchange: BSE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹526.140m
- Shares outstanding: 1.20m
- Website: https://www.mercurylabs.com
Number of Employees
Location
- Mercury Laboratories Limited
- 2/13-14, Gorwa Industrial Estate
- Gorwa Road
- Vadodara
- Gujarat
- 390016
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 538964 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Feb 2015 |
Biography
Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare in Asia, Africa, the Far East, and in ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/28 12:42 |
| End of Day Share Price | 2020/10/28 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.